The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
INDIANAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisit...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sigilon Ther...
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share....
Shares of Sigilon Therapeutics Inc (NASDAQ: SGTX) soared more than 500% today after Eli Lilly & Co (NYSE: LLY) said it will buy the biopharmaceutical company in a deal worth up to $309.6 million. Deta...
Eli Lilly said it will acquire Sigilon Therapeutics in an all-cash deal worth up to $309.6 million....
Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies that can provide longer-term solutions for di...
Sigilon Therapeutics (NASDAQ: SGTX ) stock is rocketing on Thursday morning after Eli Lilly (NYSE: LLY ) agrees to acquire the company. The acquisition will see Eli Lilly pay $14.92 per share in cash...
INDIANAPOLIS and CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to...
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through it...